The American healthcare system currently operates under a pricing model where list prices serve as opening bids rather than final costs. Amy Compton-Phillips, M.D., of CVS Health, argues that this structure creates a disorienting environment for patients and employers. While insurance companies and Pharmacy Benefit Managers (PBMs) negotiate these prices down, the invisible flow of rebates and fees often obscures the actual financial burden on the consumer.

Recent legislative shifts, including the passage of PBM reform, emphasize a growing demand for market simplicity. The argument is that removing middlemen without addressing underlying list prices would merely grant manufacturers more leverage. Instead, the focus is shifting toward transparency that allows patients to navigate care with confidence. This transparency is crucial as the system moves toward more automated and data-driven reimbursement models.

Simultaneously, the regulatory landscape for health technology faces setbacks. Reports of scrapped laboratories within the Coalition for Health AI (CHAI) — an organization developing safety standards for medical algorithms — suggest that establishing standardized algorithmic governance is proving difficult. As AI begins to play a larger role in pricing and triage, the failure to establish robust oversight labs creates a vacuum in ethical implementation within the clinical ecosystem.

The American healthcare system currently operates under a pricing model where list prices serve as opening bids rather than final costs. Amy Compton-Phillips, M.D., of CVS Health, argues that this structure creates a disorienting environment for patients and employers. While insurance companies and Pharmacy Benefit Managers (PBMs) negotiate these prices down, the invisible flow of rebates and fees often obscures the actual financial burden on the consumer.

Recent legislative shifts, including the passage of PBM reform, emphasize a growing demand for market simplicity. The argument is that removing middlemen without addressing underlying list prices would merely grant manufacturers more leverage. Instead, the focus is shifting toward transparency that allows patients to navigate care with confidence. This transparency is crucial as the system moves toward more automated and data-driven reimbursement models.

Simultaneously, the regulatory landscape for health technology faces setbacks. Reports of scrapped laboratories within the Coalition for Health AI (CHAI) — an organization developing safety standards for medical algorithms — suggest that establishing standardized algorithmic governance is proving difficult. As AI begins to play a larger role in pricing and triage, the failure to establish robust oversight labs creates a vacuum in ethical implementation within the clinical ecosystem.